OUTCOMES AND ESTIMATIONS
angina, TED, TAO, SE, depression
SECONDARY, STD, TAO
As shown in Table Comparison means of endpoints before and after intervention within treatment groups.Abbreviations: AF, angina frequency; AS, angina stability; DBP, diastolic blood pressure; GEE, generalized estimation equation; HR, heart rate; HRR: heart rate recovery; PL, physical limitation; QOL, quality of life; SBP, systolic blood pressure; STD, ST depression; TAO, time to angina onset; TED, treadmill exercise duration; TS, treatment satisfaction.Follow‐up mean ± SE of endpoints and measurements after adjustment for baseline values.Obtained from paired sample Obtained from Wilcoxon signed‐rank test.Logarithmic transformation was performed to assess the normality assumption. Anti‐log of transformed values reported.Regarding secondary outcomes, there was no significant alteration in the placebo group except for QOL and AS, which were not significantly improved in comparison with the empagliflozin group after adjustment for baseline values. Adjusted models have also indicated the higher means of both primary and secondary endpoints in patients receiving Empagliflozin compared to the placebo group, except for PL. Figure Mean changes (95% confidence interval [CI]) of endpoints (follow‐up minus baseline) in the treatment group.A 10‐point change (clinically significant improvement) in SAQ domains.Abbreviations: AF, angina frequency; AS, angina stability; PL, physical limitation; QOL, quality of life; TS, treatment satisfaction.Obtained from Fisher's exact test using Monte Carlo simulations.Obtained from As shown in Table Comparison of adverse side effects between treatment groups.obtained from Fisher's exact test using Monte Carlo simulations.